feedback

Course Director

Robin L. Jones, MD
Robin L. Jones, MD

Royal Marsden Hospital and Institute of Cancer Research
London, England, United Kingdom

Faculty

Emanuela Palmerini
Emanuela Palmerini, MD, PhD

IRCCS Istituto Ortopedico Rizzoli
Bologna University
Bologna, Italy

William Tap
William Tap, MD

Memorial Sloan Kettering Cancer Center
New York, New York

Accredited by

Medical Learning Institute, Inc.

Activity Description

PeerView’s latest online activity, based on a live symposium held adjunct to the CTOS 2020 Annual Meeting CTOS in Tokyo, addresses the newest treatment developments for rare and typically benign, tenosynovial giant cell tumor (TGCT), and provides a multidisciplinary look at how novel targeted therapeutics have enhanced the long-standing treatment landscape. This intimate, mentor-based, CME/MOC/CC-certified activity sheds light on a historically difficult-to-treat connective tissue tumor and the science that is providing hope for patients with TGCT. Don’t miss this unique educational opportunity.

Target Audience

This activity has been designed to meet the educational needs of oncologists, orthopedic oncologists, orthopedic surgeons, pathologists, and other clinicians involved in the management of connective tissue tumors.

Educational Objectives

Upon completion of this activity, participants should be better able to:
  • Discuss the clinical signs and aggressive course of rare connective tissue tumors, including tenosynovial giant cell tumor
  • Cite the biologic rationale and clinical evidence for the use of targeted options in the management of rare connective tissue tumors
  • Develop multidisciplinary approaches for the recognition and treatment of connective tissue tumors, including rare nonmalignant disorders

Providership, Credit, and Support


This CME/MOC/CC activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

This activity is supported by an educational grant from Daiichi Sankyo, Inc.

Physician Continuing Medical Education


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit™ into European CME credit (ECMEC) should contact the UEMS ( www.uems.eu).

MOC Statement

ABIM MOCSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared with ABIM through the ACCME’s Program and Activity Reporting System (PARS). Blinded individual or aggregated participant data may be shared with the funder of the activity.

Continuing Certification Statement

The activity titled “Putting Tenosynovial Giant Cell Tumor on Notice: Multidisciplinary Treatment and Implications of New Science” has been registered to offer 1.5 Patient Safety and Lifelong Learning (Part II) credits in the American Board of Pathology’s (ABPath) Continuing Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABPath Continuing Certification (formerly Maintenance of Certification or MOC) credit.

Participation information will be shared with ABPath through the ACCME’s Program and Activity Reporting System (PARS). Blinded individual or aggregated participant data may be shared with the funder of the activity.

Faculty Disclosures

Chair
Robin L. Jones, MD
Consultant Oncologist and Head of Sarcoma Unit
Royal Marsden Hospital and Institute of Cancer Research
London, England, United Kingdom

Robin L. Jones, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Adaptimmune; Blueprint Medicines Corporation; Clinigen Group plc; Daiichi Sankyo, Inc.; Deciphera Pharmaceuticals, Inc.; Eisai Co., Ltd.; Epizyme®, Inc.; Immune Design; Lilly; Merck Sharp & Dohme; PharmaMar; TRACON Pharmaceuticals, Inc.; and UpToDate, Inc.
Grant/Research Support from GlaxoSmithKline and Merck Sharp & Dohme.

Faculty
Emanuela Palmerini, MD, PhD
Chemotherapy Unit, IRCCS Istituto Ortopedico Rizzoli
Department of Experimental, Diagnostic and Specialty Medicine (DIMES)
Bologna University
Bologna, Italy

Emanuela Palmerini, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Daiichi Sankyo Company, Limited; Deciphera Pharmaceuticals, Inc.; and EUSA Pharma.

William Tap, MD
Medical Oncologist
Chief, Sarcoma Medical Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

William Tap, MD, has a financial interest/relationship or affiliation in the form of:
Consulting and/or Advisor for Adaptimmune Therapeutics plc; Agios, Inc.; Atropos Therapeutics Inc.; Blueprint Medicines Corporation; Certis Oncology Solutions; Companion diagnostics for CDK4 Inhibitors; Daiichi Sankyo Company, Limited; Eli Lilly and Company; Eisai Inc.; EMD Serono, Inc.; GlaxoSmithKline; Immune Design; Janssen Pharmaceuticals, Inc.; Loxo Oncology; NanoCarrier Co., Ltd.; and Novartis Pharmaceuticals Corporation.
Other Financial or Material Support from Research and Development/Patent Pending with Memorial Sloan Kettering Cancer Center.

Planning Committee Disclosures

The planners from Medical Learning Institute, Inc., the accredited provider, and PeerView Institute for Medical Education, the joint provider, do not have any financial relationships with an ACCME-defined commercial interest related to the content of this accredited activity during the past 12 months unless listed below.

Content/Peer Reviewer Disclosures

The following Content/Peer Reviewers have nothing to disclose:

Jim Zhai, MD, FCAP
Bobbie Perrin, FNP-C, OCN

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees for participating in or receiving credit for this accredited activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@peerview.com.

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain MOC/CC credit. There are no pre-requisites and there is no fee to participate in this activity or to receive MOC/CC credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

About This CME/MOC/CC Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

Copyright © 2000-2019, PeerView

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.